IP Library › Granted Patent US 10,800,815
Granted Patent B2
US 10,800,815 · App. 16/281,861 · Granted Oct 13, 2020

Kv1.3 potassium channel antagonists

Inventors: Andreas Klostermann (Martinsried, DE); Jörg Stockhaus (Martinsried, DE)
Assignee: Select ION Therapeutics GMBH
C07K14/00C07K14/4703C07K14/705A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,800,815
App. No.
16/281,861
Granted
Oct 13, 2020
Kind
B2
Abstract

The present disclosure provides compounds that selectively bind and inhibit potassium channel Kv1.3.

Claims (4)

1. A method of inhibiting a potassium channel Kv1.3 in a subject in need thereof, comprising administering a composition comprising a peptide of the sequence of SEQ ID NO: b 25 to said subject.

2. The method of claim 1 , further comprising selecting said subject to receive a Kv1.3 potassium channel antagonist.

3. The method of claim 1 , wherein said composition is administered intravenously, subcutaneously, or intramuscularly.

4. The method of claim 2 , wherein said composition is administered intravenously, subcutaneously, or intramuscularly.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2019
From: CGTX-PEPTIDE DEVELOPMENT GMBH
To: SELECTION THERAPEUTICS GMBH
Reel/Frame 050751/0013 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2019
From: KLOSTERMANN, ANDREAS; STOCKHAUS, JORG
To: CONOGENETIX BIOSCIENCES GMBH
Reel/Frame 050754/0263 →
SECURITY INTEREST Recorded Oct 17, 2019
From: CONOGENETIX BIOSCIENCES GMBH
To: CGTX-PEPTIDE DEVELOPMENT GMBH
Reel/Frame 050756/0833 →
Priority Claims (1)
GB 1408135.0 · May 8, 2014 · national
Continuity (2)
Continuation 15309781
Related Publication 20190375795A1 · Dec 12, 2019